Given the accumulating evidence relating high SK2 expression to oncogenesis in other types of cancers, we first investigated the expression level of SK2 in patients with MM and the correlation between SK2 expression and clinical outcomes. This evidence concerns the gene SPHK2 and Miyoshi myopathy.